Avax Technologies Announces Publication of Data on Its Autologous Cell Vaccine - Article and Editorial published in the Journal of Clinical Oncology - OVERLAND PARK, Kan., Feb. 11 /PRNewswire-FirstCall/ -- AVAX Technologies, Inc. (BULLETIN BOARD: AVXT) announces the publication of a scientific paper on studies of its Autologous Cell (AC) Vaccine platform for the treatment of cancer. The paper, by David Berd, Professor of Medicine, Kimmel Cancer Center, Thomas Jefferson University and a consultant to the Company, was published as a lead article with an accompanying editorial in the February 1, 2004 issue of the Journal of Clinical Oncology. The paper is a follow-up to previously reported clinical results on 214 patients with clinical stage III melanoma who received the AC Vaccine after standard surgery. Almost all surviving patients had completed the planned five-year follow-up. The overall five-year survival for the 214 patients was 44%. It is particularly interesting that over half ofthese patients were stage IIIC, which has a particularly poor cure rate after surgery alone. Berd and his coworkers found that an immune response to unmodified autologous melanoma cells, measured by delayed-type hypersensitivity (DTH), was induced in 47% of the patients. Significantly the survival of the DTH- positive group was double that of the DTH-negative patients. These results indicate that the DTH response can be a very important intermediate end point that can be used for further development of the technology. Richard Rainey, President of AVAX stated, "We are happy that these clinical results have been published. It is particularly gratifying that that the journal considered this paper important enough to commission an editorial. The overall survival and the relationship between survival and DTH will serve as valuable markers for us in the continuing development of this therapeutic regimen given that this study confirmed the finding that patients who had positive DTH responses had significantly longer relapse-free and overall survival rates." Mr. Rainey stated further, "We believe that the immunopharmacological analysis of the patient data in the article clearly demonstrates two very important markers. First, the timing of an induction dose and second, the schedule of the administration of the vaccine are critical parameters affecting immunologic and clinical endpoints. We are continuing with our plans to develop this important therapeutic treatment and expanding the treatmentto a variety of other cancers." AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The Company is engaged in the research, clinical and commercial development of biological products and cancer therapeutics. In addition the Company offers contract-manufacturing services of biological products to other pharmaceutical and biotechnology companies. Except for statements that are historical, the statements in this release are "forward-looking" statementsthat are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by AVAX that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. Many important factors affect the Company's prospects, including (1) the Company's ability to obtain substantial additional funds, beyond the announced bridge loans, (2) the Company's ability to enter into and to maintain contract manufacturing agreements that are adequate to sustain its operations, (3) the Company's ability to identify a merger or acquisition partner, (4) the results of laboratory testing of our vaccine technologies and the smallmolecule compounds, (5) possible future FDA or AFSSAPS questions regarding the Company's products and manufacturing processes, (6) the Company's ability to maintain its rights under license and research funding agreements and to meeting funding requirements under its license and research funding agreements, (7) the Company's ability to demonstrate the safety and efficacy of product candidates at each stage of development and to meet applicable regulatory standards and receive required regulatory approvals, as well as other risks detailed from time to time in AVAX's public disclosure filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2002. AVAX does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events. Contact: Richard P. Rainey President AVAX Technologies, Inc. (913) 693-8491 DATASOURCE: AVAX Technologies, Inc. CONTACT: Richard P. Rainey, President of AVAX Technologies, Inc., +1-913-693-8491 Web site: http://www.avax-tech.com/

Copyright